Skip to content

Glial Tumors Electromagnetic Signature Study by MagnetoEncephaloGraphy (MEG) CONDUCTOME

Magnetoencephalographic Study of Glial Tumors Electromagnetic Signature

Status
Terminated
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02077504
Acronym
CONDUCTOME
Enrollment
28
Registered
2014-03-04
Start date
2013-09-30
Completion date
2018-01-05
Last updated
2018-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Primitive Tumor With Chirurgical Indication

Brief summary

The purpose of this study is to determine the correlation between functional MEG analysis of the tumor and its periphery and the tumor stage and treatment response.

Detailed description

A better tumor grade definition would provide an optimized surgical care, prognosis and therapeutical response evaluation.

Interventions

OTHERMEG and MRI

CONDUCTOME

Sponsors

University Hospital, Grenoble
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* more or equal than 18 years old * patient affiliated to social security or similarly regime * informed consent form signed * supra-tentorial primitive cerebral tumor

Exclusion criteria

* Pregnant women and lactating mothers * Ward of court or under guardianship * Adult unable to express their consent * Person deprived of freedom by judicial or administrative decision * Person hospitalized without their consent * Person under legal protection * Magnetic Resonance Imaging (MRI) contraindication (implanted material non MRI-compatible, ferro-magnetic foreign body, claustrophobia) * Patients needed emergency medical care for other pathology * severely altered general health (Performance Status 3 or 4)

Design outcomes

Primary

MeasureTime frame
Magnetoencephalography (MEG) and Magnetic Resonance Imaging (MRI) data in tumor grade prediction1 week before exeresis
anatomopathologic and clinical data in tumor grade prediction1 week after exeresis

Secondary

MeasureTime frame
Measurement of molecules involved in glial cells neuralisation expression in tumor samplesUp to 1 month after surgery
Tumoral growth modelisation from patient MEG and MRI dataUp to 1 month after surgery

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026